Literature DB >> 27590639

Variability of blood eosinophil count as an asthma biomarker.

Sameer K Mathur1, Paul S Fichtinger2, Michael D Evans3, Elizabeth A Schwantes2, Nizar N Jarjour2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27590639      PMCID： PMC5085834          DOI： 10.1016/j.anai.2016.08.010

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  7 in total

1.  Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.

Authors:  Steven Pascoe; Nicholas Locantore; Mark T Dransfield; Neil C Barnes; Ian D Pavord
Journal:  Lancet Respir Med       Date:  2015-04-12       Impact factor: 30.700

2.  Lebrikizumab treatment in adults with asthma.

Authors:  Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

3.  Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.

Authors:  Lynn E Katz; Gerald J Gleich; Benjamin F Hartley; Steven W Yancey; Hector G Ortega
Journal:  Ann Am Thorac Soc       Date:  2014-05

4.  Is a single blood eosinophil count a reliable marker for "eosinophilic asthma?".

Authors:  Sheldon Laurence Spector; Ricardo Antonio Tan
Journal:  J Asthma       Date:  2012-08-20       Impact factor: 2.515

5.  Dupilumab in persistent asthma with elevated eosinophil levels.

Authors:  Sally Wenzel; Linda Ford; David Pearlman; Sheldon Spector; Lawrence Sher; Franck Skobieranda; Lin Wang; Stephane Kirkesseli; Ross Rocklin; Brian Bock; Jennifer Hamilton; Jeffrey E Ming; Allen Radin; Neil Stahl; George D Yancopoulos; Neil Graham; Gianluca Pirozzi
Journal:  N Engl J Med       Date:  2013-05-21       Impact factor: 91.245

6.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

7.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245
  7 in total
  11 in total

1.  Exploring the Utility of Noninvasive Type 2 Inflammatory Markers for Prediction of Severe Asthma Exacerbations in Children and Adolescents.

Authors:  Samar P Shah; Jocelyn Grunwell; Jennifer Shih; Susan Stephenson; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2019-05-14

Review 2.  Chronic cough in adults: recommendations from an Italian intersociety consensus.

Authors:  Antonio De Vincentis; Fabio Baldi; Massimo Calderazzo; Umberto Caliceti; Gabriella Guarnieri; Francesco Lombardi; Francesco Paolo Lombardo; Stefania Maggi; Graziano Onder; Adriano Vaghi; Alessandro Zanasi; Raffaele Antonelli Incalzi
Journal:  Aging Clin Exp Res       Date:  2022-06-06       Impact factor: 3.636

3.  ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.

Authors:  Alyn H Morice; Eva Millqvist; Kristina Bieksiene; Surinder S Birring; Peter Dicpinigaitis; Christian Domingo Ribas; Michele Hilton Boon; Ahmad Kantar; Kefang Lai; Lorcan McGarvey; David Rigau; Imran Satia; Jacky Smith; Woo-Jung Song; Thomy Tonia; Jan W K van den Berg; Mirjam J G van Manen; Angela Zacharasiewicz
Journal:  Eur Respir J       Date:  2020-01-02       Impact factor: 16.671

Review 4.  Identification and treatment of T2-low asthma in the era of biologics.

Authors:  Chris Kyriakopoulos; Athena Gogali; Konstantinos Bartziokas; Konstantinos Kostikas
Journal:  ERJ Open Res       Date:  2021-06-07

5.  Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children.

Authors:  Sheel N Shah; Jocelyn R Grunwell; Ahmad F Mohammad; Susan T Stephenson; Gerald B Lee; Brian P Vickery; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-27

6.  Asthma phenotype: Clinical, physiological, and biochemical profiles of North Indian patients.

Authors:  R Naveen Vennilavan; Sonam Spalgais; Raj Kumar
Journal:  Lung India       Date:  2022 Mar-Apr

7.  Variability of Type 2 inflammatory markers guiding biologic therapy of severe asthma: A 5-year retrospective study from a single tertiary hospital.

Authors:  Hongwen Li; Qing Zhang; Jingru Wang; Shengnan Gao; Chunxiao Li; Jianxin Wang; Shuhua Zhang; Jiangtao Lin
Journal:  World Allergy Organ J       Date:  2021-09-21       Impact factor: 4.084

8.  Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland.

Authors:  Mika J Mäkelä; Helene Nordahl Christensen; Antti Karlsson; Sarang Rastogi; Kirsi Kettunen
Journal:  Eur Clin Respir J       Date:  2018-04-15

9.  A Comprehensive Analysis of the Stability of Blood Eosinophil Levels.

Authors:  Bradley E Chipps; Nizar Jarjour; William J Calhoun; Ahmar Iqbal; Tmirah Haselkorn; Ming Yang; Jochen Brumm; Jonathan Corren; Cecile T J Holweg; Mona Bafadhel
Journal:  Ann Am Thorac Soc       Date:  2021-12

10.  Persistence of Eosinophilic Asthma Endotype and Clinical Outcomes: A Real-World Observational Study.

Authors:  Trung N Tran; Marjan Kerkhof; Victoria Carter; David B Price
Journal:  J Asthma Allergy       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.